PRESS RELEASE published on 01/24/2024 at 14:00, 2 years 2 months ago AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement AiCuris and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to discover new active agents for the treatment and prophylaxis of infections of immunocompromised patients. The partnership aims to develop novel therapies for patients with high medical need. The financial details of the collaboration were not disclosed. For more information, visit www.dzif.de and www.aicuris.com. AiCuris German Center For Infection Research Collaboration License Option Agreement Immunocompromised Patients
PRESS RELEASE published on 09/28/2023 at 14:00, 2 years 6 months ago AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients
PRESS RELEASE published on 08/23/2023 at 14:00, 2 years 7 months ago AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
PRESS RELEASE published on 07/06/2023 at 14:00, 2 years 9 months ago AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients
PRESS RELEASE published on 04/04/2023 at 14:00, 3 years ago AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary
Published on 04/07/2026 at 15:00, 2 hours 13 minutes ago Karbon-X Expands Enterprise Climate Platform Through Strategic Partnership with carbon-connect AG
Published on 04/07/2026 at 14:45, 2 hours 28 minutes ago Predictiv AI Introduces Clinical AI Reasoning Platform, Files Patent for Domain-Specific Clinical AI Methodology
Published on 04/07/2026 at 14:40, 2 hours 33 minutes ago bioEnergy Development Inc. Advances Domestic Activated Carbon Production Worth Up to $30 Million Over 5 Years
Published on 04/07/2026 at 14:30, 2 hours 43 minutes ago Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Published on 04/07/2026 at 14:30, 2 hours 43 minutes ago Sekur Private Data Announces Philip Oakley and Kenneth Rogers as Members of Strategic Advisory Board
Published on 04/07/2026 at 16:32, 41 minutes ago Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.
Published on 04/07/2026 at 16:30, 43 minutes ago From Old Channel to New Garden: How Chaoyang’s 'Sakura River' is Dazzling Spring
Published on 04/07/2026 at 15:00, 2 hours 13 minutes ago Amrize Announces Date for First Quarter 2026 Financial Results
Published on 04/07/2026 at 14:55, 2 hours 18 minutes ago Original-Research: Delticom AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 04/07/2026 at 14:42, 2 hours 31 minutes ago Evotec to Receive Approx. $100 Million as Part of Tubulis Acquisition
Published on 04/07/2026 at 16:43, 30 minutes ago Exercice de l’option de remboursement de l'instrument subordonné FR0010318386
Published on 04/07/2026 at 16:43, 30 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010318386
Published on 04/07/2026 at 16:18, 55 minutes ago NRJ Group - Information relative aux droits de vote au 31.03.2026 (French & English)
Published on 04/07/2026 at 14:44, 2 hours 29 minutes ago Statement of transactions in own shares from March 30, 2026 to April 2, 2026
